Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 10/20 | 0.81 |
| ▸ | NOS1 | P29475 | 10/20 | 0.81 |
| ▸ | NOS2 | P35228 | 10/20 | 0.81 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NISCH | Q9Y2I1 | 4/20 | 0.38 |
| ▸ | TOP2A | P11388 | 2/20 | 0.36 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5563390 | 1.00 | NOS3 (0.81) | NOS3NOS1NOS2MEN1KMT2A | |
| SCHEMBL5563394 | 1.00 | NOS3 (0.81) | NOS3NOS1NOS2MEN1KMT2A | |
| SCHEMBL3538758 | 0.97 | — | — | |
| Iodide SCHEMBL10973537 | 0.95 | — | — | |
| SCHEMBL105170 | 0.90 | — | — | |
| Bromide SCHEMBL2295025 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL3368438 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL3568949 | 0.87 | — | — | |
| Nitric Acid SCHEMBL10980928 | 0.82 | NOS3 (0.61) | NOS3NOS1NOS2MEN1KMT2A | |
| SCHEMBL127079 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155712-A1 | Compounds for the inhibition of angiogenesis and use thereof | JERINI AG (DE) | 2007-07-05 | — | — | US | claimed |
| US-8501787-B2 | Compounds for the inhibition of angiogenesis and use thereof | SHIRE ORPHAN THERAPIES GMBH (DE) | 2013-08-06 | — | — | US | disclosed |
| US-20070155712-A1 | Compounds for the inhibition of angiogenesis and use thereof | JERINI AG (DE) | 2007-07-05 | — | — | US | disclosed |
| WO-2005090329-A9 | NEW COMPOUNDS FOR THE INHIBITION OF ANGIOGENESIS AND USE OF THEREOF | JERINI AG (DE) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155712-A1 | Compounds for the inhibition of angiogenesis and use thereof | ITGAV, VCAM1, ITGA5 | NOS3 1193/4885NOS1 1225/4885NOS2 1034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.